Longitudinal practical measurement of skin color and moisture during and after breast-conserving therapy: influence of neoadjuvant systemic therapy

Yamazaki, Hideya; Yoshida, Ken; Kotsuma, Tadayuki; Kuriyama, Kinya; Masuda, Norikazu; Nishimura, Takuya; Kobayashi, Kana; Tsubokura, Takuji

doi:10.1007/s11604-009-0345-0

Cited by 19 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This issue (optimal organ at risk for radiation dermatitis) could be left for further investigation. Actually, until now, larger breast has been identified as an important predictor of radiation dermatitis (8)(9)(10)(11)(12)(13)(14). Also, in this study, V5 (whole body) and V40 (skin volume) showed strong correlations to body mass index.…”

Section: Variablessupporting

confidence: 60%

“…Several influential factors have been reported for radiation dermatitis. Larger breast volume, lower radiotherapy energy, larger irradiated volume, boost irradiation, and absence of skin care elevated severe radiation dermatitis (8)(9)(10)(11)(12)(13)(14). Inhomogeneity of radiation dose distribution also caused severe radiation dermatitis.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, erythema occurred in more than 90% of the patients after standard radiotherapy, while 10% developed erythema of grade 3 or 4 in the 20th century (6). The influential factors for severe radiation dermatitis have been reported (7)(8)(9)(10)(11)(12)(13)(14). High dose irradiation is one of the most important predictors of severity of both acute and late dermatitis and is associated with increased breast dose inhomogeneity and a resultant high irradiated volume (hot spots) (8)(9)(10)(11)14).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Correlation Between Dosimetric Parameters and Acute Dermatitis of Post-operative Radiotherapy in Breast Cancer Patients

Takenaka

Yamazaki

Suzuki

et al. 2018

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: To examine the correlation between dosimetric parameters and acute radiation dermatitis in early breast cancer patients subjected to post-operative radiotherapy. Patients and Methods: The data of 84 patients treated with post-operative radiotherapy were analyzed. The total prescribed dose was 50 Gy in 25 fractions over 5 weeks. Radiation dermatitis was assessed according to Common Terminology Criteria for Adverse Events v4.0. We set organ at risk whole body (from neck to abdomen examined by CT images) also as surrogate skin volume (3 mm thickness). Results: A total of 28 patients showed radiation dermatitis grade equal or higher than 2 at the 50 Gy time point. These 28 patients were compared to 56 matched pair patients with grade 0-1 radiation dermatitis during the same treatment period. The mean of V5-20 and V40 in patient's whole volume and V40-50 in skin volume were significantly higher in patients who presented with acute radiation dermatitis Grades ≥2 than in the other patients who did not. The statistically most significant difference was observed for V40 for skin volume and V5 for patient whole volume. Rate of acute radiation dermatitis grade ≥2 was significantly higher for patients with V5 (whole body) >1,360 cm 3 than those with V5 (whole body) <1,360 cm 3 (47% vs. 27%, p=0.0353), as well as for patients with V40 (skin volume) >45 cm 3 compared with those with V40 (skin volume) <45 cm 3 (50% vs. 18%, p=0.0043). Conclusion: Dosimetric parameters were useful to predict radiation dermatitis grade ≥2. V5 (whole body) 1,360 cm 3 and V40 (skin volume) 45 cm 3 may be dose volume constrain for radiation dermatitis grade ≥2.

show abstract

Section: Variablessupporting

confidence: 60%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Correlation Between Dosimetric Parameters and Acute Dermatitis of Post-operative Radiotherapy in Breast Cancer Patients

Takenaka

Yamazaki

Suzuki

et al. 2018

In Vivo

Self Cite

View full text Add to dashboard Cite

show abstract

“…The pre-WBRT WC ratio (WCR (0) = I 0 / N 0 , irradiated breast skin WC divided by contralateral breast WC) was calculated. Taking intra- and inter-individual variation ( 5 ) into account, RWCR ( t ) , (WCR normalized by pre-WBRT state) was then calculated using the following formula ( 11 )

where I 0 and I t correspond to WC on the irradiated breast at pre-WBRT and each study point, and N 0 and N t correspond to WC on the non-irradiated breast at pre-WBRT and each study point.…”

Section: Methodsmentioning

confidence: 99%

“…It measures the electrical capacitance of the skin surface as an indicator of stratum corneum hydration, which is dependent on the high dielectrical constant of WC relative to other skin components. The corneometer has been demonstrated to be useful for objectively assessing radiation induced skin reactions for breast cancer patients ( 11 ). Skin-related signs and symptoms were also assessed.…”

Section: Introductionmentioning

confidence: 99%

Randomized, prospective assessment of moisturizer efficacy for the treatment of radiation dermatitis following radiotherapy after breast-conserving surgery

Sekiguchi

Ogita

Akahane

et al. 2015

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

ObjectiveThe effect of heparinoid moisturizer use after acute skin damage for patients receiving whole-breast radiotherapy after lumpectomy is understudied.MethodsA total of 30 patients were randomly assigned to receive heparinoid moisturizer (Group M), and 32 patients comprised the control group (Group C). Patients in Group M were instructed to apply heparinoid moisturizer from 2 weeks following whole-breast radiotherapy, and to continue to use the moisturizer until 3 months after completion of whole-breast radiotherapy. Group C patients were instructed to not apply any topical moisturizer during the study period. The relative ratio of skin water content ratio (RWCR(t) = (It /Nt)/(I0/N0)) between irradiated and non-irradiated field was calculated. Signs and symptoms were also assessed. The primary endpoint was the difference in relative ratio of skin water content ratio between 2 and 4 weeks following whole-breast radiotherapy.ResultsIn Group C, relative ratio of skin water content ratio dropped to 0.80 ± 0.15 at 2 weeks and maintained the low level at 4 weeks following whole-breast radiotherapy. Similarly, in Group M, relative ratio of skin water content ratio dropped to 0.81 ± 0.19 at 2 weeks (prior to application), however, it returned to baseline level (1.05 ± 0.23) at 4 weeks (2 weeks after application). The arithmetic difference of relative ratio of skin water content ratio in Group M was 0.24 ± 0.23 and was significantly larger than in Group C (0.06 ± 0.15; P < 0.01). Skin dryness and desquamation were less severe in Group M.ConclusionsThe application of heparinoid moisturizer for 2 weeks following whole-breast radiotherapy significantly increased water content and helped improve skin dryness and desquamation compared with no use of moisturizer.

show abstract

Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo‐controlled trial in breast cancer patients (TRANSDERMIS trial)

et al. 2018

View full text Add to dashboard Cite

show abstract

Longitudinal practical measurement of skin color and moisture during and after breast-conserving therapy: influence of neoadjuvant systemic therapy

Abstract: Objective analysis is useful for detailed assessment of radiation dermatitis. NST did not worsen skin reactions.

Cited by 19 publications

References 12 publications

Correlation Between Dosimetric Parameters and Acute Dermatitis of Post-operative Radiotherapy in Breast Cancer Patients

Correlation Between Dosimetric Parameters and Acute Dermatitis of Post-operative Radiotherapy in Breast Cancer Patients

Randomized, prospective assessment of moisturizer efficacy for the treatment of radiation dermatitis following radiotherapy after breast-conserving surgery

Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo‐controlled trial in breast cancer patients (TRANSDERMIS trial)

Contact Info

Product

Resources

About